All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Clinical comparison

Cosyntropin (Cortrosyn) vs Sincalide (Kinevac)

An educational, source-based comparison of Cosyntropin (Cortrosyn) and Sincalide (Kinevac) — how each peptide works, what it's researched for, and what to know before going deeper.

Diagnostic · Endocrine
Cosyntropin (Cortrosyn)

Synthetic ACTH(1-24) for adrenal function testing.

Mechanism

Synthetic peptide containing the first 24 amino acids of ACTH — retains full corticotropic activity. Stimulates adrenal cortisol release for diagnostic testing.

Research areas
  • Primary and secondary adrenal insufficiency diagnosis
Considerations
  • FDA-approved.
  • Single diagnostic dose; very well tolerated.
Full Cosyntropin (Cortrosyn) profile →
CCK Analog · Diagnostics
Sincalide (Kinevac)

Synthetic C-terminal octapeptide of cholecystokinin for gallbladder imaging.

Mechanism

Synthetic CCK-8 that binds CCK-A receptors on gallbladder smooth muscle, triggering contraction; used to assess gallbladder ejection fraction in cholescintigraphy.

Research areas
  • Gallbladder ejection fraction (HIDA scan)
  • Pancreatic secretion testing
  • Small bowel transit imaging
Considerations
  • FDA-approved.
  • Abdominal cramping, nausea, diarrhea common; contraindicated in suspected gallstone obstruction.
Full Sincalide (Kinevac) profile →

Trial-evidence rating

Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.

Cosyntropin (Cortrosyn)
Strong

FDA-approved with published clinical trial data.

1 cited study
Sincalide (Kinevac)
Strong

FDA-approved with published clinical trial data.

1 cited study

Study-by-study comparison

PeptideStudySourceYearSummary
Cosyntropin (Cortrosyn)Low-dose vs standard cosyntropin stimulationJCEM2008Comparison of 1 mcg vs 250 mcg testing for secondary adrenal insufficiency.
Sincalide (Kinevac)Standardized sincalide cholescintigraphy guidelineJ Nucl Med2010Established 60-minute infusion as optimal for reproducible GBEF.

Side-effect & safety grid

Cosyntropin (Cortrosyn)
  • FDA-approved.
  • Single diagnostic dose; very well tolerated.
Sincalide (Kinevac)
  • FDA-approved.
  • Abdominal cramping, nausea, diarrhea common; contraindicated in suspected gallstone obstruction.

Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.

Cosyntropin (Cortrosyn) vs Sincalide (Kinevac) — Key differences

  • Class: Cosyntropin (Cortrosyn) is classified as Diagnostic · Endocrine, while Sincalide (Kinevac) is CCK Analog · Diagnostics.
  • Primary research focus: Cosyntropin (Cortrosyn)primary and secondary adrenal insufficiency diagnosis; Sincalide (Kinevac)gallbladder ejection fraction (hida scan).
  • Tag: FDA-Approved · Diagnostic vs FDA-Approved · Diagnostics.

Related comparisons